FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1475-1484 November 30, 1995 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

A variety of skin diseases, autoimmune and inherited, are characterized by the presence of blisters. In some, such as pemphigus vulgaris, blistering is the primary manifestation. In others, such as lichen planus, blisters are infrequent. Most of these diseases are associated with substantial morbidity; a few may result in death. Although the general approach to the treatment of these diseases is similar, the diagnosis of the specific disease is important, because the most appropriate dosage and timing of some commonly used medications vary considerably. This review covers the management of the major acquired bullous diseases; diseases only rarely associated with . . . [Full Text of this Article]

Autoimmune Bullous Diseases

Systemic Corticosteroid Therapy

Topical Corticosteroid Therapy

Other Immunosuppressive Drugs

Dapsone and Related Drugs

Chrysotherapy

Plasmapheresis

Dietary Interventions

Other Therapies

Erythema Multiforme and Stevens–Johnson Syndrome

Systemic Corticosteroid Therapy

Other Immunosuppressive Drugs

Acyclovir and Erythema Multiforme

Other Therapeutic Options

Toxic Epidermal Necrolysis

General Principles of Treatment

Systemic Corticosteroid Therapy

Conclusions

Source Information

From the Departments of Dermatology and Epidemiology, University of North Carolina at Chapel Hill; and the National Epidermolysis Bullosa Registry — both in Chapel Hill, N.C.

Address reprint requests to Dr. Fine at the Department of Dermatology, University of North Carolina at Chapel Hill, Suite 3100, Thurston Bldg., CB# 7287, Chapel Hill, NC 27599.

References

Related Letters:

Management of Acquired Bullous Skin Diseases
Guibal F., Roujeau J.-C., Stern R. S., Weissel M., Fine J.-D.
Extract | Full Text  
N Engl J Med 1996; 334:864-865, Mar 28, 1996. Correspondence

This article has been cited by other articles:

• Bernard, P., Reguiai, Z., Tancrede-Bohin, E., Cordel, N., Plantin, P., Pauwels, C., Vaillant, L., Grange, F., Richard-Lallemand, M.-A., Sassolas, B., Roujeau, J.-C., Lok, C., Picard-Dahan, C., Chosidow, O., Vitry, F., Joly, P. (2009). Risk Factors for Relapse in Patients With Bullous Pemphigoid in Clinical Remission: A Multicenter, Prospective, Cohort Study. Arch Dermatol 145: 537-542 [Abstract] [Full Text]  
• Iwata, Y., Komura, K., Kodera, M., Usuda, T., Yokoyama, Y., Hara, T., Muroi, E., Ogawa, F., Takenaka, M., Sato, S. (2008). Correlation of IgE Autoantibody to BP180 With a Severe Form of Bullous Pemphigoid. Arch Dermatol 144: 41-48 [Abstract] [Full Text]  
• Beissert, S., Werfel, T., Frieling, U., Bohm, M., Sticherling, M., Stadler, R., Zillikens, D., Rzany, B., Hunzelmann, N., Meurer, M., Gollnick, H., Ruzicka, T., Pillekamp, H., Junghans, V., Bonsmann, G., Luger, T. A. (2007). A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid. Arch Dermatol 143: 1536-1542 [Abstract] [Full Text]  
• Joly, P., Benichou, J., Lok, C., Hellot, M. F., Saiag, P., Tancrede-Bohin, E., Sassolas, B., Labeille, B., Doutre, M. S., Gorin, I., Pauwels, C., Chosidow, O., Caux, F., Esteve, E., Dutronc, Y., Sigal, M., Prost, C., Maillard, H., Guillaume, J. C., Roujeau, J. C. (2005). Prediction of Survival for Patients With Bullous Pemphigoid: A Prospective Study. Arch Dermatol 141: 691-698 [Abstract] [Full Text]  
• Boosinger, A. B., Thomas, H. L. (2002). Stevens-Johnson Syndrome Secondary to Vancomycin Exposure. Journal of Pharmacy Practice 15: 515-518 [Abstract]  
• Joly, P., Roujeau, J.-C., Benichou, J., Picard, C., Dreno, B., Delaporte, E., Vaillant, L., D'Incan, M., Plantin, P., Bedane, C., Young, P., Bernard, P., the Bullous Diseases French Study Group, (2002). A Comparison of Oral and Topical Corticosteroids in Patients with Bullous Pemphigoid. NEJM 346: 321-327 [Abstract] [Full Text]  
• Sirois, D. A., Fatahzadeh, M., Roth, R., Ettlin, D. (2000). Diagnostic Patterns and Delays in Pemphigus Vulgaris: Experience With 99 Patients. Arch Dermatol 136: 1569-1570 [Full Text]  
• SIROIS, D., LEIGH, J. E., SOLLECITO, T. P. (2000). ORAL PEMPHIGUS VULGARIS PRECEDING CUTANEOUS LESIONS: RECOGNITION AND DIAGNOSIS. Journal of the American Dental Association 131: 1156-1160 [Abstract] [Full Text]  
• Pandya, A. G., Dyke, C. (1998). Treatment of Pemphigus With Gold. Arch Dermatol 134: 1104-1107 [Abstract] [Full Text]  
• Guibal, F., Roujeau, J.-C., Stern, R. S., Weissel, M., Fine, J.-D. (1996). Management of Acquired Bullous Skin Diseases. NEJM 334: 864-865 [Full Text]